MGEN News and Press, Miragen Therapeutics Inc. From 05/07/20

Miragen Therapeutics (NASDAQ: MGEN ): Q1 GAAP EPS of -$0.18 beats by $0.03 . Revenue of $0.83M (+124.3% Y/Y) beats by $0.24M . Press Release More news on: Miragen Therapeutics, Earnings news and commentary, Healthcare stocks news, ,

New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020 Additional NIH grant funding released in support of MRG-229 for IPF; preclinical studies progressing as planned with additional data...

BOULDER, Colo., April 23, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its first quarter 2020 financial results after the fina...

Miragen Therapeutics (NASDAQ: MGEN ) has filed a prospectus  for a $175M mixed shelf offering. More news on: Miragen Therapeutics, Healthcare stocks news, , Stocks on the move, Read more ...

miRagen Therapeutics, Inc. (MGEN) Q4 2019 Earnings Conference Call March 11, 2020, 04:30 PM ET Company Participants Dan Ferry - Managing Director of LifeSci Advisors Bill Marshall - President and CEO Diana Escolar - Chief Medical Officer Jason Leverone - CFO Conference Call ...

Miragen Therapeutics (NASDAQ: MGEN ): Q4 GAAP EPS of -$0.31 misses by $0.06 . More news on: Miragen Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Completed enrollment of 37 patients in the Phase 2 SOLAR trial of cobomarsen in CTCL; expects to report topline data in Q3 2020 Completed initial planned enrollment of the Phase 1 trial of cobomarsen in ATLL patients; reported additional data in January 2020; expects to meet with the F...

BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced it will report its fourth quarter and full year 2019 financial results ...

Gainers: Benitec Biopharma (NASDAQ: BNTC )  +51% . More news on: Benitec Biopharma Limited, Assertio Therapeutics, Inc., Ocwen Financial Corporation, Stocks on the move, , Read more ...

BOULDER, Colo., Feb. 07, 2020 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of an underwritten public offering of 15,000,000 shares of ...